Content Detail

• Content META

  Title	3i : Half Yearly Report 2024
  ID	4411380
  External ID	7300856556
  Author	Unknown
  Published Date	Nov. 14, 2024, 3:22 a.m.
  Summary	3i Group plc announces results for the six months to 30 September 2024 3i Group delivered good financial performance in the first half of FY2025 Total return of £2,046 million or 10% on opening sha
  Tags	None
  URL	https://www.marketscreener.com/quote/stock/3i-group-plc-4007143/news/3i-half-yearly-report-2024-48362087/
  Sentiment	Negative: 0.01977    Neutral: 0.03474    Positive: 0.94549
  Relevance	0.04091

• Content Details

  Content ID	2628855
  Key	2c16c98a-2e38-44f0-9e6d-432ddab850e1
  Content	3i Group plc announces results for the six months to 30 September 2024 3i Group delivered good financial performance in the first half of FY2025 Total return of £2,046 million or 10% on opening shareholders' funds (September 2023: £1,669 million, 10%). NAV per share of 2,261 pence (31 March 2024: 2,085 pence), including a 48 pence per share loss on foreign exchange translation (September 2023: 11 pence per share loss), and after the payment of the 34.50 pence per share second FY2024 dividend in July 2024. Our Private Equity business delivered a gross investment return of £2,071 million or 11% (September 2023: £1,826 million, 11%). Action continues to deliver impressive results, and the majority of our other portfolio companies are trading resiliently against mixed macroeconomic performance across Europe and the US and wider geopolitical uncertainty. 94% of our Private Equity portfolio companies by value grew earnings in the 12 months to 30 June 2024. Action generated net sales of €9,567 million (nine reporting periods ended P9 2023: €7,912 million), operating EBITDA of €1,344 million (nine reporting periods ended P9 2023: €1,065 million) and like-for-like ("LFL") sales growth of 9.8% in the nine reporting periods ending on 29 September 2024 ("P9"). This strong performance supported value growth of £2,170 million for Action in the period. Following another successful refinancing and pro- rata share redemption, 3i received proceeds of £1,164 million from Action in the period and we reinvested a total of £768 million, increasing our gross equity stake from 54.8% to 57.9%. In the ten reporting periods ending 27 October 2024, Action's net sales and operating EBITDA were 21% and 26% ahead of the same period last year and LFL sales growth over the same period was 10.1%. At that date, Action's cash balance was €830 million. Our Private Equity team completed the realisation of nexeye and signed the realisation of WP in the period. Total proceeds generated of £662 million, achieving sterling money multiples of 2x or greater. The team also completed a new investment in Constellation (£98 million) and a further five bolt-on acquisitions, the majority of which were funded from the portfolio companies' own balance sheets. Our Infrastructure business generated a gross investment return of £43 million, or 3% (September 2023: £31 million, 2%). This was driven primarily by a 4% increase in 3i Infrastructure plc's ("3iN") share price in the six-month period to 30 September 2024. 3iN's underlying portfolio continues to perform well, and exits have been achieved at premiums to the opening 31 March 2024 values, as evidenced by the offer received for Valorem and by the partial syndication of Future Biogas. We also completed two bolt-on acquisitions for two investments in our North American Infrastructure Fund. We ended the period with liquidity of £1,286 million, net debt of £805 million and gearing of 4%. The first dividend of 30.5 pence per share for FY2025, set at 50% of the total dividend for FY2024, will be paid in January 2025. Simon Borrows, 3i's Chief Executive, commented: "Against an uncertain geopolitical environment and weak growth across much of Europe, we move into the second half of FY2025 with a portfolio that is well positioned to build on a solid first half. Action is the major contributor to our returns and continues to produce sector-leading growth. With a strong business and financial model and significant white space to expand into, we believe it will continue to do so for many years to come. In addition, the leading companies in our portfolio are performing strongly and a number of the portfolio companies that were adversely impacted by challenges in 2023 are beginning to turn the corner and see improved trading. We have seen good momentum across our investment and realisation activity in the half and we have a good pipeline of high-quality realisations for the next 12 months. We also have some interesting potential opportunities in our investment pipeline, which we will continue to review in a disciplined way and progress those that are most attractive." Summary financial highlights under the Investment basis 3i prepares its statutory financial statements in accordance with UK adopted international accounting standards. However, we also report a non-GAAP "Investment basis", which we believe aids users of our report to assess the Group's underlying operating performance. The Investment basis (which is unaudited) is an alternative performance measure ("APM") and is described on page 19. Total return and net assets are the same under the Investment basis and IFRS and we provide a reconciliation of our Investment basis financial statements to the IFRS statements from page 21. Pages to 18 are prepared on an Investment basis. 1 Total return is defined as Total comprehensive income for the year, under both the Investment basis and the IFRS basis. 2 Financial measure defined as APM. Further information on page 19. Disclaimer These half-year results have been prepared solely to provide information to shareholders. They should not be relied on by any other party or for any other purpose. These half-year results may contain statements about the future, including certain statements about the future outlook for 3i Group plc and its subsidiaries ("3i" or "the Group"). These are not guarantees of future performance and will not be updated. Although we believe our expectations are based on reasonable assumptions, any statements about the future outlook may be influenced by factors that could cause actual outcomes and results to be materially different. Enquiries: A PDF copy of this release can be downloaded from www.3i.com/investor-relations For further information, including a live webcast of the results presentation at 10.00am on 14 November 2024, please visit www.3i.com/investor-relations 3i Group Half-year report 2024 Chief Executive's review The Group delivered good financial performance in the first half, generating a total return of £2,046 million in the six months to 30 September 2024, or 10% on opening shareholders' funds (September 2023: £1,669 million, 10%). NAV per share at 30 September 2024 was 2,261 pence (31 March 2024: 2,085 pence), including a 48 pence per share loss on foreign exchange translation (September 2023: 11 pence per share loss) and after the payment of the 34.50 pence per share second FY2024 dividend in July 2024. Action continues to produce impressive results, with sales, EBITDA and cash generation ahead of our expectations. We received proceeds of £1,164 million from Action in the period, following another successful refinancing and pro-rata share redemption, and subsequently completed a significant reinvestment of £768 million, further increasing our ownership position. Despite a muted macroeconomic backdrop across Europe and moderate growth in the US economy, the majority of our other portfolio companies have demonstrated resilient performance in the period, and we are seeing the gradual unwind of some of the challenges which weighed on performance in 2023. Against a difficult realisation market, which is showing some signs of improvement, we secured two significant Private Equity realisations, generating total proceeds of £662 million, both at sterling money multiples of 2x or greater, and one at a good premium to our 31 March 2024 value. Likewise, our Infrastructure business maintained its track record of delivering significant uplifts on exit, following the receipt of a binding offer for an existing portfolio company and a partial syndication of another. We also deployed capital into a new Private Equity investment and saw good buy-and-build momentum across both portfolios in the period. Private Equity The Private Equity portfolio delivered a gross investment return ("GIR") of £2,071 million in the period, or 11% on opening value. This includes a £456 million loss on foreign exchange translation, after the impact of foreign exchange hedging, due to the strengthening of sterling in the period. Action generated a GIR of £1,827 million in the period, or 13% over its opening value. In the 12 months to the end of 30 June 2024, 94% of our portfolio companies by value grew earnings. Action performance In the nine reporting periods ending on 29 September 2024 ("P9"), Action generated net sales of €9,567 million (nine reporting periods ended P9 2023: €7,912 million) and operating EBITDA of €1,344 million (nine reporting periods ended P9 2023: €1,065 million), 21% and 26% ahead of the same period last year. Over the same period, LFL sales growth was 9.8%, driven by strong growth in customer transactions, outperformance in everyday necessities and a small negative price effect. LFL sales growth for the same period last year was 19.2%. Action's strategy of passing through deflation in purchase prices to customers and sharing the benefits of increasing buying power continues to resonate well with Action's customers in what remains a tough cost of living environment. Action generated an EBITDA margin of 14.0% in the first nine reporting periods of the year compared to 13.5% in the same period last year and remains focused on cost discipline against industry-wide upward pressure on, amongst others, wages and container prices. Action added 189 stores in the first nine reporting periods of the year (nine reporting periods ended P9 2023: 153 stores) and is now on track to add approximately 350 stores this year. Its store roll-out across Italy, Portugal, Slovakia and Spain, its most recent expansion markets, is ahead of our expectations. In July 2024, Action successfully completed a refinancing event, raising €2.1 billion in total, including a second US dollar term loan of $1.5 billion and a €700 million term loan. It also completed a capital restructuring with a pro-rata redemption of shares, returning £1,164 million (€1,374 million) of gross proceeds to 3i. Alongside a number of existing LPs in the 2020 Co-Investment Programme, 3i took the opportunity to acquire further shares in Action and, including one small further purchase of an existing LP stake in Action later in the period, 3i reinvested a total of £768 million in Action, increasing 3i's gross equity stake from 54.8% to 57.9%. At 30 September 2024, Action was valued using the last 12 months ("LTM") run-rate earnings to 29 September 2024 of €2,065 million. This includes our normal run-rate adjustment to reflect stores opened in the last 12 months. At that date, Action's valuation net debt, post the refinancing event, comprised total senior debt of c.€6.6 billion and cash of €733 million, resulting in a net debt to run-rate EBITDA ratio of 2.9x. Our valuation multiple remains unchanged at 18.5x net of the liquidity discount, resulting in a valuation of £15,543 million (31 March 2024: £14,158 million) for 3i's 57.9% equity stake at 30 September 2024. Action continues to outperform a broad range of discount competitors, across all relevant operating KPIs. Its consistent and unrelenting focus on the customer is what gives us confidence in its ability to continue to execute its growth opportunity in existing and new countries. Action's excellent growth meant its valuation at 30 September 2023 of 18.5x LTM run-rate EBITDA translated to 14.6x of the run-rate EBITDA achieved a year later. Strong trading momentum has continued into Action's P10 (30 September 2024 to 27 October 2024), generating net sales of €1,166 million and operating EBITDA of €188 million for that reporting period. Cash at the end of P10 was €830 million and Action added a further 31 stores in P10, taking the total number of stores added to 220 in the ten reporting periods to 27 October 2024. Action has good product availability ahead of the key trading period in the remainder of the final quarter of the year. Other Private Equity portfolio performance The Private Equity portfolio, excluding Action, delivered a GIR of £244 million, or 4% on opening value in the period, or 6% excluding the net loss on foreign exchange translation. Our portfolio companies operating in the value-for-money and private label sectors have continued to perform well and we are also seeing some encouraging developments across some of our industrial and healthcare assets. Royal Sanders continued to deliver significant organic growth in the first half of 2024, with strong volumes across its key customers, supported by outperformance across its bolt-on acquisitions. The most recent self-funded acquisition of Karium, a platform of established brands across the hair care, body care and skin care categories, strengthens the brands division within Royal Sanders and provides significant growth opportunities. European Bakery Group ("EBG") traded resiliently in the period, despite pressure on selected input costs and wage inflation. After a period of strong cash generation, EBG returned proceeds of £22 million to 3i, within 12 months of 3i's further investment to support the acquisition of coolback in 2023. Audley Travel performed strongly across its US and UK markets in the period and continues to demonstrate an excellent post-Covid recovery. It continues to gain share in both markets. MPM continues to grow well across all of its markets, in particular the US, its largest market. After a challenging 2023, Tato saw a good recovery in sales volumes and improved profitability in the first half of 2024. While its input costs have largely stabilised, a tougher competitive dynamic is driving pricing pressure across its end markets and is expected to persist through the second half of 2024. Cirtec Medical delivered strong top-line growth and improved margins in the period, driven by increased demand from customers across its product range and by operational improvements. The business continues to see a robust pipeline across its end markets and has a number of new programmes that will launch into production during late 2024 and the first half of 2025. SaniSure saw encouraging bookings momentum in the first half of 2024 and, while the recovery has not been linear, momentum has continued through the second half of 2024 and the order book development is pointing to a more positive 2025, as customer destocking ends and normal ordering patterns return. Whilst a broader recovery across the bioprocessing market has taken longer than expected, market consensus is for a return to attractive growth in 2025-2026. MAIT completed two further bolt-on acquisitions in the period and has traded resiliently, as its focus on mission-critical enterprise resource planning and product lifecycle management areas has limited the impact of softening discretionary spending on IT hardware. xSuite is making good progress with its SaaS transition plan, with recurring sales performing ahead of expectations. WilsonHCG continues to operate through a weak white-collar recruitment market. Against this backdrop, the business has maintained its core customer base through strong service and secured new customer wins, while right sizing its resourcing and operations for the current lower demand environment. We invested a further £4 million in WilsonHCG in the period to support the near-term requirements of the business. Konges Sløjd has seen softer business-to-business sales across its main geographies but has maintained stable margins. Private Equity investment and realisation activity Despite some signs of improvement, the Private Equity transaction market remains challenging. Against this backdrop, we have maintained our price discipline and deployed our capital selectively, whilst continuing our rigorous focus on asset management. We invested £98 million in Constellation , an IT managed services provider specialised in hybrid cloud and cyber security. We have also continued to support the development of ten23 health , our contract development and manufacturing organisation ("CDMO") platform, with a further investment of £30 million. We secured two significant realisations in the period. In July 2024, we completed the sale of nexeye , a company which we supported financially when its stores were closed during stages of the pandemic and which doubled its sales and EBITDA during our period of ownership. This realisation achieved a small profit over 31 March 2024 value and returned proceeds of £382 million which, combined with distributions already received during our ownership, resulted in a sterling money multiple of 2.0x. In July 2024, we also signed an agreement to sell our stake in WP , in which we initially invested in 2015 and which has since grown to become a leading provider of innovative plastic packaging solutions with a strong presence across Europe and Latin America. This transaction completed in October 2024, at an 18% profit over 31 March 2024 value, delivering proceeds of £280 million including interest income of £3 million which, combined with the £45 million of proceeds received earlier in our period of ownership, results in a sterling money multiple of 2.2x. Infrastructure In the six months to 30 September 2024, our Infrastructure portfolio generated a GIR of £43 million, or 3% on opening value. 3iN generated a total return on its opening NAV of 5.1% in the six months to 30 September 2024, resulting in a NAV of 374.7 pence per share, driven by good underlying portfolio performance. Tampnet performed well in the period, supported by revenue growth in its fixed units in the North Sea and Gulf of Mexico and TCR continues to see strong demand for its rental offering. SRL has, however, seen softer trading across its core rental business as a result of a wider market downturn. In the period, 3iN invested £30 million to support Future Biogas 's acquisition of a 51% stake in a portfolio of six anaerobic digestion plants. At the end of September 2024, 3iN completed the syndication of 23% of its stake in Future Biogas to an external investor, at a 15% uplift on 31 March 2024 value. At the beginning of October 2024, 3iN received a binding offer for its stake in Valorem . Subject to acceptance of the offer, the expected net proceeds of €309 million represent a 15% uplift on 31 March 2024 value and a money multiple of 3.5x. 3iN's share price increased to 341 pence at 30 September 2024 (31 March 2024: 327 pence). Whilst this increase in the share price largely reflects improved market sentiment for the infrastructure asset class, 3iN continues to trade at a discount to its 30 September 2024 NAV, even after several periods of outperformance from its portfolio and the business delivering another realisation significantly above carrying value. We have seen good buy-and-build momentum in our North American Infrastructure Fund with both Regional Rail and Amwaste completing bolt-on acquisitions in the period. Smarte Carte commenced cart operations in London Heathrow in June 2024, and steady US and international passenger numbers were reflected in its volumes across its various offerings in the period. Scandlines continues to show resilience. The leisure segment had a record peak summer season, whilst freight remained stable against a benign macroeconomic backdrop. Cash generation remains strong and 3i received a dividend of £12 million from Scandlines in the period. Balance sheet, liquidity, foreign exchange and dividend We ended the period with cash of £386 million (31 March 2024: £396 million) and total liquidity of £1,286 million (31 March 2024: £1,296 million), including an undrawn RCF of £900 million. Net debt was £805 million, with gearing of 4% (31 March 2024: £806 million, 4%). Since the end of the period, we received proceeds of £280 million from the realisation of WP. We continued to reduce the carried interest liability associated with Action, with carry crystallisation payments totalling £283 million in the period, meaning our equity stake in Action, after the reinvestment in the period and net of the carried interest liability, has increased to 57.4% (31 March 2024: 53.2%). Going forward, the Buyouts 2010-12 vintage (which relates to our investment in Action) will accrue net carried interest payable at a rate of less than 1% (31 March 2024: c.3%) of Action's GIR. Due to the strengthening of sterling in the period, we recorded a total foreign exchange translation loss of £466 million (September 2023: £107 million loss), including a gain on foreign exchange hedging. In line with our dividend policy, we will pay a first FY2025 dividend of 30.5 pence per share, which is half of our FY2024 total dividend. This first FY2025 dividend will be paid to shareholders on 10 January 2025. Outlook Against an uncertain geopolitical environment and weak growth across much of Europe, we move into the second half of FY2025 with a portfolio that is well positioned to build on a solid first half. Action is the major contributor to our returns and continues to produce sector-leading growth. With a strong business and financial model and significant white space to expand into, we believe it will continue to do so for many years to come. In addition, the leading companies in our portfolio are performing strongly and a number of the portfolio companies that were adversely impacted by challenges in 2023 are beginning to turn the corner and see improved trading. We have seen good momentum across our investment and realisation activity in the half, and we have a good pipeline of high-quality realisations for the next 12 months. We also have some interesting potential opportunities in our investment pipeline, which we will continue to review in a disciplined way and progress those that are most attractive. Simon Borrows Chief Executive 13 November 2024 Business and Financial review Private Equity Our Private Equity portfolio generated a GIR of £2,071 million (September 2023: £1,826 million), or 11% of the opening portfolio value (September 2023: 11%), including a loss on foreign exchange on investments, after the impact of foreign exchange hedging, of £456 million (September 2023: £127 million loss). Table 1: Gross investment return for the six months to 30 September Investment and realisation activity In July 2024, Action raised €2.1 billion in a refinancing event and also completed a capital restructuring with a pro-rata redemption of shares. 3i received total proceeds £1,164 million from this share redemption. 3i, alongside a number of existing LPs in the 2020 Co-Investment Programme, took the opportunity to acquire further shares in Action and, including one small further purchase of an existing LP stake in Action later in the period, it reinvested a total of £768 million in Action, increasing 3i's gross equity stake from 54.8% to 57.9%. In the period, we invested £98 million to acquire Constellation , a hybrid cloud and cybersecurity managed services provider, which is well positioned to be a key consolidator in a fragmented IT services French market. We also invested a total of £44 million across further and bolt-on investments, of which £30 million related to a further investment in ten23 health , £5 million to support xSuite 's bolt-on acquisition of tangro, and £4 million to support WilsonHCG through current market headwinds. Following good performance and cash generation, we received £22 million back from EBG as a return of funding within 12 months of our investment to support its acquisition of coolback in 2023. Our portfolio companies completed four self-funded bolt-on acquisitions, including two for MAIT and one for Royal Sanders , which continued their significant buy-and-build growth strategies, and one for AES , which expanded its product offering in North America. We secured two significant realisations in the period, crystallising money multiples of 2x or greater. In July 2024, we completed the sale of nexeye , which achieved a small profit over 31 March 2024 value and returned proceeds of £382 million which, combined with distributions already received during our ownership, resulted in a sterling money multiple of 2.0x. In July 2024, we also agreed the realisation of WP . This transaction completed in October 2024, at an 18% profit over 31 March 2024 value, delivering proceeds of £280 million which, combined with the £45 million of proceeds received earlier in the period of ownership, results in a sterling money multiple of 2.2x. In total, in the period to 30 September 2024, 3i invested £888 million in Private Equity (September 2023: £50 million) and generated total proceeds of £1,548 million (September 2023: £1 million). Table 2: Private Equity cash investment in the six months to 30 September 2024 Table 3: Private Equity portfolio bolt-on acquisitions funded by the portfolio company in the six months to 30 September 2024 Table 4: Private Equity realisations in the six months to 30 September 2024 1 Cash proceeds realised in the period less opening value. 2 Profit in the year over opening value. 3 Cash proceeds over cash invested. Money multiples are quoted on a GBP basis. Portfolio performance Table 5: Unrealised profits/(losses) on the revaluation of Private Equity investments in the six months to 30 September 1 More information on our valuation methodology, including definitions and rationale, is included in our Annual report and accounts 2024 on page 217. Action performance and valuation As detailed in the Chief Executive's review, Action performed strongly in the period. At 30 September 2024, Action continued to be valued using its LTM run-rate earnings to the end of P9 2024 of €2,065 million, which included our normal adjustment to reflect stores opened in the last 12 months. We continue to value Action at a multiple of 18.5x net of the liquidity discount (31 March 2024: 18.5x). Its performance across key operating KPIs continues to compare favourably against all peers that we use to benchmark its results. Whilst the overall average multiple of the peer group reduced marginally in the period, the top quartile peers within this group continue to outperform and maintain their premium rating. In addition, recent transactions with 3i and various LPs in the co-investment vehicles have taken place at a 3i carrying value of Action, providing further support for our valuation mark. Action ended P9 2024 with a cash balance of €733 million and a net debt to LTM run-rate earnings ratio of 2.9x. This result is after the refinancing event which took place in July 2024. At 30 September 2024, the valuation of our 57.9% stake in Action was £15,543 million (31 March 2024: 54.8%, £14,158 million). We recognised unrealised profits from Action of £2,170 million (September 2023: £1,810 million), as shown in Table 5. Table 6: Action financial metrics Performance (excluding Action) Excluding Action, the Private Equity portfolio valued on an earnings basis generated £319 million of value growth from performance increases in the period (September 2023: £353 million), more than offsetting £66 million of performance decreases (September 2023: £219 million). Royal Sanders performed strongly in the period, with continued growth at key customers and its recent bolt-on acquisitions, including the most recent self-funded acquisition of Karium. EBG sustained good trading in the period despite persistent pricing and input cost headwinds, demonstrating the high quality of the business. Audley Travel saw impressive UK and US booking volumes in the period and is expecting a strong end to 2024, with full coverage across its order book already achieved. MPM continues to grow its presence in the US market, while continuing to outperform in its more mature markets. Tato returned to growth in the first half of 2024, as end-market demand has gradually improved, resulting in increased volumes. Its margins have benefitted from substantially lower input costs compared to the prior year. Tato continues to experience intensifying pricing competition, which is expected to persist through the second half of 2024. Commercial traction at Cirtec Medical has led to a robust pipeline across all parts of its business, with demand from new and existing customers contributing to a positive result in the period. SaniSure saw solid improvement across all of its key metrics in the first half of 2024 and is making good progress in strategic initiatives across high value R&D developments. While the recovery from post-Covid destocking has not been entirely linear, leading to inconsistent near- term trading, bookings momentum remains strong and indicative of a return to attractive growth in 2025-2026. MAIT traded resiliently in the period despite softer IT hardware spend in its markets. Its recent bolt-on acquisitions position the business well for further consolidation of a fragmented market and for capitalising on increasing demand for its services. Operating in a similar market environment, Evernex has delivered stable top line growth, benefitting from significant contract wins towards the end of 2023. xSuite 's SaaS transition is well progressed, leading to an increased proportion of recurring revenue. tangro, its most recent acquisition, is already contributing to the business positively. Over the last 18 months, reduced employee turnover and lower new hiring activity has impacted the US recruitment industry, impacting performance at WilsonHCG . A recovery to more typical turnover levels remains slow as employees continue to "stay put", albeit we are beginning to see some initial encouraging indicators across the US economy. We will continue to support Wilson through these headwinds. We have seen some softer performance from Konges Sløjd , which is being impacted by a slowdown in orders following constrained customer spending, as well as from Dynatect , which has been impacted by the delayed ramp of a key contract. Overall, 94% of our Private Equity portfolio companies by value grew LTM adjusted earnings in the 12 months to 30 June 2024. 1 Based on LTM adjusted earnings to June 2024. Includes 29 companies. Attachments Original document Permalink Disclaimer 3i Group plc published this content on November 14, 2024 , and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on November 14, 2024 at
  Content Reference URL	None

• Publisher

  Publisher Name	MarketScreener (#4446)
  Publisher URL	http://www.marketscreener.com
  Description	None
  Trust Flow Score	23
  Citation Flow Score	26

• Data Source

  Data Source Name	Quantexa News (#5)
  Data Source Type	news
  Data Source URL	https://app.aylien.com/dashboard
  Description	Welcome to Quantexa News API — the most powerful way to aggregate, filter, and integrate global news data into your apps and models.
  Weight	10